Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.46 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | FPR1 | P21462 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10328699 | 0.83 | ADORA1 (0.47) | ADORA1TMIGD3MAPTTDP1NPC1 | |
| SCHEMBL24963293 | 0.81 | ADORA1 (0.50) | ADORA1TMIGD3MAPTTDP1NPC1 | |
| SCHEMBL12071042 | 0.81 | MAPT (0.41) | ADORA1TMIGD3MAPTTDP1NPC1 | |
| SCHEMBL3799860 | 0.81 | ADORA1 (0.46) | ADORA1TMIGD3MAPTTDP1NPC1 | |
| SCHEMBL2678119 | 0.81 | ADORA1 (0.46) | ADORA1TMIGD3MAPTTDP1NPC1 | |
| Lithium Ion SCHEMBL3799858 | 0.80 | MAPT (0.47) | ADORA1TMIGD3MAPTTDP1NPC1 | |
| SCHEMBL21200063 | 0.80 | MAPT (0.47) | ADORA1TMIGD3MAPTTDP1NPC1 | |
| SCHEMBL22518536 | 0.77 | ADORA1 (0.47) | ADORA1TMIGD3MAPTTDP1NPC1 | |
| SCHEMBL31135495 | 0.75 | ADORA1 (0.41) | ADORA1TMIGD3MAPTTDP1NPC1 | |
| SCHEMBL4769460 | 0.75 | TMIGD3 (0.41) | ADORA1TMIGD3MAPTTDP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393493-A1 | COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-12-14 | — | — | EP | disclosed |
| WO-2011150190-A2 | HCV INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ANACOR PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| EP-2250174-A2 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX Pharmaceuticals, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20100196321-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100196321-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100196321-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-05 | — | — | US | disclosed |
| WO-2010088394-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088394-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2009099596-A2 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARAMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196321-A1 | COMPOUNDS | HAVCR2, ACE, ACE2 | ADORA1 2051/4885TMIGD3 4653/4885MAPT 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.